Patent ID: 9499632
Filing Date: 2016-11-22
CPC Classification: A61K,A61P,C07K

Claim Text:
1. A method of treating a CD22-expressing B cell cancer in a subject comprising administering to the subject a monoclonal antibody or an antigen-binding portion thereof, which specifically binds to CD22, in an amount effective to treat the cancer, wherein the monoclonal antibody or antigen-binding portion thereof comprises: (a) a heavy chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:2; (b) a heavy chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:6 or SEQ ID NO:60; (c) a heavy chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:10; (d) a light chain variable region CDR1 comprising amino acids having the sequence set forth in SEQ ID NO:14; (e) a light chain variable region CDR2 comprising amino acids having the sequence set forth in SEQ ID NO:20; and (f) a light chain variable region CDR3 comprising amino acids having the sequence set forth in SEQ ID NO:26.